David B.Alden

Dave Alden's litigation practice focuses on product liability matters and, in particular, on actions involving prescription drugs, medical devices, tobacco, and consumer products. Dave has been pretrial, trial, and appellate counsel in matters throughout the United States. He regularly counsels clients regarding attorney-client privilege and work product issues, and Ohio's attorney-client privilege statute was amended as first advocated in Dave's law review article.

Dave has been national coordinating counsel for major clients, including R.J. Reynolds in smoking and health actions and prescription drug manufacturers in actions relating to antidepressants and opioids. He represented Bayer in an arbitration challenging Bayer's decision to terminate development of a hemophilia product in which Bayer prevailed on all claims. Dave previously was in-house counsel at a major accounting firm.

Dave coauthored Drug and Device Product Liability Litigation Strategy (Oxford Univ. Press 2d ed. 2018); "Voluntary Client Testimony As A Privilege Waiver: Is Ohio's Law Caught In A Time Warp?," 59(1) Clev. St. L. Rev. 1 (2011); and "The Meaning Of The Parallel Requirements Exception Under Lohr and Riegel," 65(3) N.Y.U. Ann. Surv. Am. L. 545 (2010). Since 2011, he has authored the Ohio chapter of Product Liability Desk Reference: A Fifty-State Compendium (Wolters Kluwer 2022).

Dave's pro bono representations include Raymond Towler, who was exonerated based on new DNA testing after 29 years in prison, and Douglas Prade, who was excluded from male DNA found over the murderer's bite on the victim.